Compare · ALHC vs ILMN
ALHC vs ILMN
Side-by-side comparison of Alignment Healthcare Inc. (ALHC) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALHC and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.93B, about 6.6x ALHC ($4.38B).
- Over the past year, ALHC is up 59.9% and ILMN is up 96.7% - ILMN leads by 36.8 points.
- ILMN has been more active in the news (10 items in the past 4 weeks vs 8 for ALHC).
- Both have 25 recent analyst ratings on file.
- Company
- Alignment Healthcare Inc.
- Illumina Inc.
- Price
- $21.22+4.12%
- $191.24+0.57%
- Market cap
- $4.38B
- $28.93B
- 1M return
- +4.89%
- +15.15%
- 1Y return
- +59.91%
- +96.69%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2000
- News (4w)
- 8
- 10
- Recent ratings
- 25
- 25
Alignment Healthcare Inc.
Alignment Healthcare, Inc. provides a consumer-centric platform that delivers customized health care to seniors in the United States. It offers medicare advantage plans and health plan options to its partners and patients with customized care and service; and preferred provider organization offerings. The company was founded in 2013 and is based in Orange, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ALHC
- Chief Executive Officer Kao John E sold $5,919,361 worth of shares (298,000 units at $19.86) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Alignment Healthcare Inc.
- Alignment Healthcare to Announce Second Quarter 2026 Financial Results and Host Conference Call Thursday, July 30, 2026
- Chief Operations Officer Hochradel Shane J. was granted 87,719 shares (SEC Form 4)
- EVP, Corporate Affairs Konowiecki Joseph S sold $600,000 worth of shares (25,000 units at $24.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,103,816 units (SEC Form 4)
- SEC Form 144 filed by Alignment Healthcare Inc.
- EVP, Corporate Affairs Konowiecki Joseph S sold $575,000 worth of shares (25,000 units at $23.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,128,816 units (SEC Form 4)
- SEC Form 144 filed by Alignment Healthcare Inc.
- EVP, Corporate Affairs Konowiecki Joseph S sold $550,000 worth of shares (25,000 units at $22.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,153,816 units (SEC Form 4)
- SEC Form 144 filed by Alignment Healthcare Inc.
Latest ILMN
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors